ANA-ENA, LIA 17 IgG at Test Zone Diagnostic Center

ANA-ENA, LIA 17 IgG at Test Zone Diagnostic Center

The ANA-ENA, LIA 17 IgG is a highly specialized, multiplexed serological assay designed to detect and differentiate 17 distinct autoantibodies of the Immunoglobulin G (IgG) class in human serum. This comprehensive panel is a cornerstone in the diagnostic evaluation of Systemic Autoimmune Rheumatic Diseases (SARD), which encompass a broad spectrum of chronic inflammatory conditions characterized by the immune system’s loss of self-tolerance. By targeting specific nuclear and cytoplasmic antigens, this assay provides clinicians with invaluable diagnostic, prognostic, and therapeutic monitoring data. Test Zone Diagnostic Center in Lahore, Pakistan, utilizes state-of-the-art Line Immunoassay (LIA) technology to deliver precise, reproducible, and clinically actionable results for patients presenting with complex autoimmune symptoms.

The Line Immunoassay works by utilizing a nitrocellulose membrane strip onto which highly purified, recombinant, or native antigens are applied as thin, parallel lines. When a patient’s serum is incubated with the strip, any specific IgG autoantibodies present will bind to their corresponding antigen lines. After washing away unbound proteins, a secondary enzyme-conjugated anti-human IgG antibody is introduced, followed by a chromogenic substrate. The development of distinct dark bands indicates a positive reaction, the intensity of which can be evaluated visually or densitometrically. This multiplex format allows for the simultaneous screening of 17 critical autoantibodies from a single blood draw, offering unparalleled diagnostic efficiency compared to sequential single-antigen testing.

The clinical utility of the ANA-ENA, LIA 17 IgG panel lies in its ability to resolve the fine specificity of antinuclear antibodies (ANA). While traditional indirect immunofluorescence (IIF) on HEp-2 cells remains the gold standard for ANA screening, it only indicates the presence of autoantibodies and their general staining pattern. The LIA 17 IgG panel goes a step further by identifying the exact molecular targets of these antibodies, such as double-stranded DNA (dsDNA), Smith (Sm) antigen, Sjögren’s syndrome-related antigens A and B (SSA/SSB), and various other nuclear and cytoplasmic proteins. This high-resolution profiling is essential for distinguishing between overlapping autoimmune syndromes, predicting organ involvement (such as lupus nephritis or pulmonary fibrosis), and establishing early therapeutic interventions to prevent irreversible tissue damage.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure specimen integrity and accurate results. For the ANA-ENA, LIA 17 IgG test at Test Zone Diagnostic Center, patients should observe the following guidelines:

• No Fasting Required: Fasting is generally not mandatory for this serological test. Patients may consume food and fluids normally prior to the blood draw.
• Hydration: Adequate hydration is highly recommended, as it facilitates easier venous access and smooth sample collection.
• Medication Disclosure: Patients must inform their referring physician and the laboratory staff of all ongoing medications, particularly immunosuppressants, systemic corticosteroids, and biological therapies. These medications can suppress antibody production, potentially leading to lower antibody titers or false-negative results.
• Timing of the Test: Unless clinically contraindicated, it is often preferred to collect the sample before initiating high-dose immunosuppressive therapy to capture the baseline autoantibody profile.

During the Procedure

The sample collection process is a standard venipuncture performed by skilled phlebotomists at Test Zone Diagnostic Center. The procedure is designed to minimize patient discomfort and ensure a sterile environment:

• Patient Positioning: The patient is seated comfortably, and the arm is extended and supported on a stable surface.
• Site Selection and Cleansing: The phlebotomist identifies a suitable vein, typically the median cubital vein in the antecubital fossa. The skin is thoroughly cleansed with a 70% isopropyl alcohol swab in a circular motion and allowed to air dry.
• Venipuncture: A tourniquet is applied 3 to 4 inches above the puncture site to increase venous pressure. A sterile, single-use needle attached to a vacuum collection tube (typically a gold-top serum separator tube or a red-top plain tube) is inserted into the vein.
• Sample Collection: Approximately 3 to 5 milliliters of blood are drawn. Once the tube is filled, the tourniquet is released, the needle is gently withdrawn, and immediate pressure is applied to the site with a sterile gauze pad.
• Post-Procedure Care: A sterile adhesive bandage is applied to the puncture site. The patient is advised to keep the bandage on for at least an hour and avoid heavy lifting with that arm. The collected blood is allowed to clot completely before undergoing centrifugation to separate the serum for LIA analysis.

When is a ANA-ENA, LIA 17 IgG Performed?

Suspected Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus is a prototype autoimmune disease characterized by multi-organ inflammation and a vast array of autoantibodies. Physicians request the ANA-ENA, LIA 17 IgG panel when a patient presents with classic symptoms of SLE, such as a malar (butterfly) rash, photosensitivity, non-erosive arthritis, unexplained fever, persistent fatigue, and signs of renal involvement like proteinuria. The detection of specific antibodies like anti-dsDNA and anti-Sm within this panel is highly diagnostic for SLE and helps differentiate it from other connective tissue diseases.

Evaluation of Sjögren’s Syndrome

Sjögren’s syndrome is a chronic autoimmune disorder primarily affecting the exocrine glands, leading to severe dryness of the eyes (keratoconjunctivitis sicca) and mouth (xerostomia). It can occur independently (primary) or in association with other autoimmune diseases (secondary). The ANA-ENA, LIA 17 IgG panel is indicated when patients present with these sicca symptoms, recurrent dental caries, parotid gland enlargement, or systemic manifestations like joint pain and peripheral neuropathy. The presence of anti-SSA (Ro60 and Ro52) and anti-SSB (La) antibodies strongly supports the diagnosis of Sjögren’s syndrome.

Investigation of Systemic Sclerosis (Scleroderma)

Systemic Sclerosis is characterized by progressive skin thickening, vascular dysfunction, and visceral fibrosis. Clinical indications for this panel include Raynaud’s phenomenon (exaggerated cold sensitivity in fingers and toes), sclerodactyly, esophageal dysphagia, and interstitial lung disease. The LIA 17 IgG panel evaluates key markers associated with systemic sclerosis, such as anti-Scl-70 (associated with diffuse cutaneous involvement and pulmonary fibrosis) and anti-CENP-B (associated with limited cutaneous involvement and CREST syndrome), aiding in risk stratification and clinical management.

Diagnosis of Mixed Connective Tissue Disease (MCTD)

Mixed Connective Tissue Disease is an overlap syndrome presenting with clinical features shared by SLE, systemic sclerosis, and polymyositis. Patients often present with swollen hands, synovitis, Raynaud’s phenomenon, and muscle weakness. The ANA-ENA, LIA 17 IgG panel is crucial in these cases because a definitive diagnosis of MCTD requires the detection of extremely high titers of anti-U1-RNP (specifically the RNP/Sm marker) in the absence of other scleroderma-specific or lupus-specific antibodies, helping clinicians tailor immunomodulatory therapy.

Assessment of Polymyositis and Dermatomyositis

Idiopathic inflammatory myopathies, including polymyositis and dermatomyositis, present with progressive, symmetric proximal muscle weakness, elevated muscle enzymes, and characteristic cutaneous lesions such as Gottron’s papules and a heliotrope rash. The LIA 17 IgG panel is performed to identify myositis-specific and myositis-associated autoantibodies, such as anti-Jo-1 (associated with antisynthetase syndrome) and anti-Mi-2 (associated with classic dermatomyositis), which guide prognosis and help monitor for associated interstitial lung disease or malignancies.

What Does a ANA-ENA, LIA 17 IgG Detect?

The ANA-ENA, LIA 17 IgG panel simultaneously detects 17 distinct autoantibodies, each targeting a specific cellular antigen. The clinical significance of these targets includes:

• Anti-dsDNA: Highly specific for Systemic Lupus Erythematosus (SLE); strongly associated with active lupus nephritis and used to monitor disease activity.
• Anti-Nucleosomes: Key marker for SLE; often present in patients with active glomerulonephritis and can appear before anti-dsDNA antibodies.
• Anti-Histones: Strongly associated with Drug-Induced Lupus Erythematosus (DILE) and also found in idiopathic SLE.
• Anti-Ribosomal P-protein: Highly specific for SLE; associated with neuropsychiatric lupus, lupus hepatitis, and active systemic disease.
• Anti-Sm (Smith): Pathognomonic for SLE; included in the ACR/EULAR classification criteria for lupus diagnosis.
• Anti-RNP/Sm (U1-RNP): Diagnostic hallmark of Mixed Connective Tissue Disease (MCTD) when present in high titers; also seen in SLE.
• Anti-SSA/Ro60: Associated with Sjögren’s syndrome, SLE, subacute cutaneous lupus, and neonatal lupus (congenital heart block).
• Anti-Ro52 (TRIM21): Frequently co-exists with Ro60; associated with inflammatory myopathies, systemic sclerosis, and neonatal lupus.
• Anti-SSB/La: Highly associated with Sjögren’s syndrome and SLE; typically presents alongside anti-SSA antibodies.
• Anti-Scl-70 (Topoisomerase I): Specific marker for diffuse cutaneous systemic sclerosis; indicates a higher risk of interstitial lung disease.
• Anti-PM-Scl: Associated with polymyositis/systemic sclerosis overlap syndrome (PM/Scl overlap) and pulmonary involvement.
• Anti-Jo-1: The most common anti-synthetase antibody; associated with myositis, interstitial lung disease, arthritis, and mechanic’s hands.
• Anti-CENP-B (Centromere Protein B): Marker for limited cutaneous systemic sclerosis (CREST syndrome); associated with a lower risk of severe pulmonary fibrosis.
• Anti-PCNA (Proliferating Cell Nuclear Antigen): Rare but highly specific marker for SLE; associated with proliferative glomerulonephritis.
• Anti-Mi-2: Specific marker for dermatomyositis; associated with classic cutaneous manifestations and a favorable response to therapy.
• Anti-Ku: Associated with overlap syndromes involving systemic sclerosis, polymyositis, and SLE.
• Anti-DFS70: Often found in healthy individuals or non-systemic autoimmune conditions; a positive DFS70 in isolation helps rule out SARD.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center in Lahore, Pakistan, we understand the anxiety and clinical urgency associated with autoimmune testing. The ANA-ENA, LIA 17 IgG panel is processed using fully automated line immunoassay systems to ensure maximum precision and eliminate manual interpretation errors. The typical turnaround time for this specialized panel is 24 to 48 hours from the time of sample collection. Once the clinical pathologists verify and sign off on the results, patients receive an automated SMS notification. Reports can be securely downloaded from the Test Zone online portal or collected physically from the main center or any of our convenient collection points across Lahore.

ANA-ENA, LIA 17 IgG Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Anti-dsDNA IgG	Negative	Positive (Highly suggestive of SLE, active lupus nephritis)
Anti-Sm IgG	Negative	Positive (Pathognomonic for SLE)
Anti-RNP/Sm IgG	Negative	Positive (Diagnostic for MCTD, also seen in SLE)
Anti-SSA/Ro60 IgG	Negative	Positive (Sjögren’s syndrome, SLE, neonatal lupus risk)
Anti-SSB/La IgG	Negative	Positive (Sjögren’s syndrome, SLE)
Anti-Scl-70 IgG	Negative	Positive (Diffuse systemic sclerosis, interstitial lung disease)
Anti-CENP-B IgG	Negative	Positive (Limited systemic sclerosis / CREST syndrome)
Anti-Jo-1 IgG	Negative	Positive (Antisynthetase syndrome, myositis, ILD)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for ANA-ENA, LIA 17 IgG?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly qualified clinical pathologists and immunologists who oversee all testing procedures.
• Patient-Focused Care: We prioritize patient comfort and clear communication throughout the diagnostic journey.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to strict internal and external quality control standards for reproducible results.
• Professional Reporting: Our reports are detailed, structured, and easy for referring physicians to interpret.
• Modern Diagnostic Approach: We utilize advanced line immunoassay (LIA) technology for high-resolution autoantibody profiling.
• Comfortable Environment: Our collection centers in Lahore offer a clean, hygienic, and welcoming atmosphere for blood draws.
• Convenient Location: Easily accessible main center and multiple collection points across Lahore, Pakistan.
• Commitment to Accurate Diagnosis: We ensure that every sample is processed with the highest level of clinical integrity and precision.